Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoQ10 in Bipolar Depression
NCT00327756Phase 2
Key facts
- Status
- Withdrawn
- Start
- May 2006
- Primary completion
- May 2009
- Countries
- 1
- Sponsor
- National Institute of Mental Health
- Modality
- Small Molecules
- Drugs
- coenzyme q10
- Conditions
- bipolar disorder (BD)
01
Overview
Phase 2, randomised, double-blind trial in bipolar disorder (BD) comparing Coenzyme Q10 with Placebo (2 arms). Primary endpoint: Brain lactate levels at 8 weeks. Planned start May 2006; status: withdrawn.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Coenzyme Q10
Coenzyme Q10 (300-1200 mg/day)
Placebo
Inactive look-alike substance
03
Endpoints
Primary
Brain lactate levels
Secondary
Montgomery-Asberg Depression Rating Scale
Beyond the preview
Go deeper on NCT00327756.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00327756.